New drug trial targets rare, severe skin condition
NCT ID NCT07497620
Summary
This study is testing if a medication called Bimzelx can improve the skin of adults with pityriasis rubra pilaris, a rare and often severe inflammatory skin disease. It will involve 12 participants who will receive the drug and be monitored for 28 weeks. The main goal is to see how many people achieve significant skin clearance, measured by a standard scoring system.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PITYRIASIS RUBRA PILARIS are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Mayo Clinic in Florida
Jacksonville, Florida, 32224, United States
Conditions
Explore the condition pages connected to this study.